Renal amyloidosis Medical Services in China

Renal amyloidosis is a rare, systemic disorder characterized by the extracellular deposition of misfolded amyloid fibrils—primarily immunoglobulin light chains (AL type) or serum amyloid A protein (AA type)—within the kidney’s glomeruli, tubules, and interstitium. These insoluble, beta-pleated sheet aggregates disrupt normal renal architecture and function, leading to progressive proteinuria, nephrotic syndrome, and ultimately end-stage kidney disease if untreated. Pathogenesis hinges on abnormal protein folding and impaired clearance: in AL amyloidosis, clonal plasma cell dyscrasia produces excess monoclonal light chains that aggregate into amyloid; in AA amyloidosis, chronic inflammatory conditions (e.g., rheumatoid arthritis, tuberculosis, or familial Mediterranean fever) drive sustained overproduction of serum amyloid A, which fragments and deposits as amyloid in tissues. Less common forms include hereditary (ATTR, APOL1-related) and dialysis-related (β2-microglobulin) variants. Epidemiologically, renal amyloidosis accounts for ~1–5% of all cases of nephrotic syndrome in adults and is significantly underdiagnosed due to nonspecific early symptoms and reliance on tissue biopsy with Congo red staining and immunohistochemistry or mass spectrometry for definitive subtyping. Incidence is estimated at 5–10 new cases per million population annually in high-income countries; AL amyloidosis peaks in the sixth to seventh decades (median age 63), with a male predominance (M:F ≈ 1.5:1); AA amyloidosis occurs across broader age groups but correlates strongly with duration and severity of underlying inflammation. Key risk factors include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, chronic infections (e.g., osteomyelitis, HIV), autoimmune diseases, and genetic predispositions (e.g., SAA1 polymorphisms). Quality of life is profoundly impacted: patients commonly experience debilitating fatigue, edema-related mobility limitations, recurrent infections due to hypoalbuminemia and immunoglobulin loss, thromboembolic events, and psychological distress—including anxiety and depression—stemming from diagnostic delays, treatment complexity, and uncertain prognosis. As renal function declines, dietary restrictions, frequent clinic visits, and eventual dialysis or transplant candidacy further erode autonomy and social participation. Early diagnosis remains critical—not only to preserve kidney function but also to address systemic involvement (e.g., cardiac, hepatic, or neurologic amyloid), which dictates overall survival. Without timely intervention, median survival in AL amyloidosis with renal involvement is <2 years; with modern risk-adapted therapy, 5-year survival now exceeds 60%. Multidisciplinary care involving nephrology, hematology, cardiology, and pathology is essential for optimal outcomes.

Renal amyloidosis is a systemic disorder characterized by extracellular deposition of misfolded amyloid fibrils—primarily derived from immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the glomeruli, interstitium, and vasculature of the kidneys. This leads to progressive proteinuria, nephrotic syndrome, declining glomerular filtration rate (GFR), and ultimately end-stage kidney disease (ESKD) if untreated. Management requires multidisciplinary coordination, with nephrology at its core, and must be tailored to the underlying amyloid type, disease burden, organ involvement, and patient comorbidities.

Conservative treatment forms the essential foundation of care and aims to mitigate complications, preserve residual renal function, and improve quality of life. Strict blood pressure control—targeting <130/80 mmHg—is achieved using renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., lisinopril, losartan), which reduce intraglomerular hypertension and proteinuria. Diuretic therapy (e.g., furosemide, often combined with spironolactone in resistant edema) addresses volume overload and hypoalbuminemia-related ascites or pleural effusions. Nutritional support includes moderate protein intake (0.8–1.0 g/kg/day) to avoid catabolism without exacerbating proteinuria; sodium restriction (<2 g/day) is critical for edema and hypertension control. Hyperlipidemia is managed with high-intensity statins (e.g., atorvastatin 40–80 mg daily), given the high prevalence of dyslipidemia in nephrotic syndrome. Thromboprophylaxis with low-molecular-weight heparin (e.g., enoxaparin 40 mg SC daily) or direct oral anticoagulants (e.g., apixaban 2.5 mg BID) is indicated in patients with serum albumin <2.5 g/dL and additional risk factors (e.g., immobility, prior thrombosis), due to the hypercoagulable state associated with AL amyloidosis and nephrotic syndrome.

Pharmacologic therapy targets the underlying amyloidogenic precursor. For AL amyloidosis—the most common renal form—first-line treatment is hematologic-directed therapy to suppress clonal plasma cell production of pathogenic light chains. The standard regimen is daratumumab (a human monoclonal anti-CD38 antibody) combined with cyclophosphamide and dexamethasone (D-CyDex), administered intravenously and orally over 6–12 months. This achieves hematologic complete response (CR) in ~60–70% of eligible patients and significantly improves renal outcomes, including stabilization or reduction in proteinuria and slower eGFR decline. Alternative regimens include bortezomib-based combinations (e.g., CyBorD: cyclophosphamide, bortezomib, dexamethasone), particularly in patients with cardiac involvement or neuropathy. For AA amyloidosis—often secondary to chronic inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, or familial Mediterranean fever—treatment focuses on controlling the underlying inflammation. Biologic agents like IL-1 inhibitors (e.g., anakinra, canakinumab) or TNF-alpha antagonists (e.g., infliximab, adalimumab) are used to suppress serum amyloid A (SAA) synthesis; sustained SAA levels <10 mg/L correlate strongly with renal amyloid regression and improved survival. In hereditary forms (e.g., ATTR amyloidosis), tafamidis—a transthyretin stabilizer—may be considered off-label in select cases, though renal involvement is less common than in cardiac or neurologic variants.

Surgical treatment has a limited but defined role. Kidney transplantation is feasible in selected patients with AL amyloidosis only after achieving deep and sustained hematologic remission (≥12 months CR confirmed by bone marrow biopsy and serum free light chain ratio normalization), absence of significant cardiac or gastrointestinal involvement, and stable organ function. Graft survival is comparable to non-amyloid recipients when strict eligibility criteria are met, with 5-year graft survival exceeding 80%. Recurrence of AL amyloid in the allograft occurs in <5% of rigorously selected cases. For AA amyloidosis, transplantation is more readily considered once the underlying inflammatory disease is controlled, with lower recurrence rates (<10%). Autologous stem cell transplantation (ASCT) remains an option for fit, younger patients (<65 years) with AL amyloidosis and adequate cardiac reserve (NT-proBNP <3,300 ng/L, troponin T <0.06 ng/mL); however, its use has declined with the advent of highly effective daratumumab-based regimens due to higher toxicity and mortality risks.

China offers distinct advantages in the management of renal amyloidosis. First, integrated national amyloidosis referral networks—centered at tertiary hospitals such as Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—provide rapid access to specialized diagnostics, including mass spectrometry-based amyloid typing (gold standard), cardiac MRI with late gadolinium enhancement, and abdominal fat pad biopsy with Congo red staining. Second, China’s robust pharmaceutical regulatory framework has accelerated approval of novel agents: daratumumab received NMPA approval for AL amyloidosis in 2022, and biosimilar versions have improved affordability and accessibility across provincial healthcare systems. Third, real-world evidence from large Chinese cohorts (e.g., the China Amyloidosis Registry) informs region-specific treatment algorithms, particularly regarding optimal dosing in patients with reduced kidney function and managing drug-induced cytopenias in Asian populations. Fourth, multidisciplinary amyloid clinics—staffed by nephrologists, hematologists, cardiologists, and genetic counselors—offer coordinated longitudinal follow-up, reducing diagnostic delays that historically averaged >18 months globally but now average <6 months in top-tier centers.

Recovery and long-term monitoring require structured, patient-centered guidance. Patients should undergo quarterly assessments including 24-hour urine protein, serum creatinine/eGFR, albumin, free light chains (kappa/lambda ratio), and NT-proBNP. Annual echocardiography and nerve conduction studies are recommended for AL patients. Lifestyle modifications include smoking cessation, influenza/pneumococcal vaccination, and avoidance of NSAIDs and iodinated contrast media. Psychological support is integral—depression and anxiety affect >40% of amyloidosis patients—and many Chinese centers now embed clinical psychologists within amyloid clinics. Dietary counseling emphasizes plant-based proteins, omega-3 fatty acids, and potassium restriction if hyperkalemic. Finally, patients must understand that renal amyloidosis is a chronic condition requiring lifelong surveillance: even in hematologic remission, late-onset renal deterioration may occur due to irreversible structural damage, underscoring the importance of early diagnosis and sustained therapeutic adherence. With timely, precise, and integrated care, many patients achieve prolonged renal stability, preserved independence, and meaningful survival extension.